Pulmonary Function Tests in Connective Tissue Disease

ABSTRACT

The interpretation of pulmonary function tests (PFTs) in patients with connective tissue disease poses considerable difficulties in clinical practice. In established lung disease, several characteristic PFT profiles are recognized for individual complications, including pulmonary fibrosis, pulmonary vascular disease, extrapulmonary restriction, and intrinsic airway disease. PFTs play a central role in the investigation of respiratory symptoms and are sensitive in the detection of interstitial lung disease and pulmonary vascular disease. The staging of disease severity using PFTs is an invaluable guide to prognosis. Maximal exercise testing has an ancillary role in selected patients and is most often useful in demonstrating that limited disease is not clinically significant. The interpretation of PFTs is most difficult when, as is commonly the case, two or more pulmonary complications coexist, each having separate functional effects. Finally, the use of PFTs in routine monitoring is discussed.

KEYWORDS

Pulmonary function tests - pulmonary fibrosis - pulmonary hypertension

REFERENCES

• 1 Gibson G J. Clinical Tests of Respiratory Function. London: Chappell and Hall 1996: 223-224
• 2 Wells A U, Hansell D M, Rubens M B, Cailes J B, Black C M, du Bois R M. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison.  Am J Respir Crit Care Med. 1997;  155 1657-1664
• 3 Cordier J-F. Organising pneumonia.  Thorax. 2000;  55 318-328
• 4 Burke C M, Glanville A R, Morris A J et al.. Pulmonary function in advanced pulmonary hypertension.  Thorax. 1987;  42 131-135
• 5 Lipscomb D J, Patel K, Hughes J M. Interpretation of increases in the transfer coefficient for carbon monoxide (TLCO/VA or KCO).  Thorax. 1978;  33 728-733
• 6 Broderick A, Fuortes L J, Merchant J A, Galvin J R, Shwartz D A. Pleural determinants of restrictive lung function and respiratory symptoms in an asbestos-exposed population.  Chest. 1992;  101 684-691
• 7 Wright P H, Hansen A, Kreel L, Capel L H. Respiratory function changes after asbestos pleurisy.  Thorax. 1980;  35 31-36
• 8 Gibson G J, Pride N B, Newsom-Davis J, Loh L C. Pulmonary mechanics in patients with respiratory muscle weakness.  Am Rev Respir Dis. 1977;  115 389-395
• 9 Vincken W G, Elleker M G, Cosio M G. Flow-volume loop changes reflecting respiratory muscle weakness in chronic neuromuscular disorders.  Am J Med. 1987;  83 673-680
• 10 Braun N M, Arora N S, Rochester D F. Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies.  Thorax. 1983;  38 616-623
• 11 Gould G A, Redpath A T, Ryan M et al.. Lung CT density correlates with measurements of airflow limitation and the diffusing capacity.  Eur Respir J. 1991;  4 141-146
• 12 Hansell D M, Rubens M B, Padley S PG, Wells A U. Obliterative bronchiolitis: individual CT signs of small airways disease and functional correlation.  Radiology. 1997;  203 721-726
• 13 Alton E, Turner-Warwick M. Lung involvement in scleroderma. In: Jayson MIV, Black CM Systemic Sclerosis: Scleroderma. London; John Wiley & Sons 1988: 181-205
• 14 Dawson J K, Fewins H E, Desmond J, Lynch M P, Graham D R. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests.  Thorax. 2001;  56 622-627
• 15 Roschmann R A, Rothenberg R J. Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy [review].  Semin Arthritis Rheum. 1987;  16 174-185
• 16 Marie I, Hatron P Y, Hachulla E, Wallaert B, Michon-Pastural U, Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis.  J Rheumatol. 1998;  25 1336-1343
• 17 Quanjer P H. Predicted values: how should we use them?.  Thorax. 1988;  43 663-664
• 18 Keogh B A, Crystal R G. Pulmonary function testing in interstitial pulmonary disease: what does it tell us?.  Chest. 1980;  78 856-865
• 19 Peters-Golden M, Wise R A, Hochberg M C, Stevens M B, Wigley F M. Carbon monoxide diffusing capacity as a predictor of outcome in systemic sclerosis.  Am J Med. 1984;  77 1027-1034
• 20 Morgan C, Knight C, Lunt M, Black C M, Silman A J. Predictors of end stage lung disease in a cohort of patients with scleroderma.  Ann Rheum Dis. 2003;  62 146-150
• 21 Steen V D, Conte C, Owens G R, Medsger Jr T A. Severe restrictive lung disease in systemic sclerosis.  Arthritis Rheum. 1994;  37 1283-1289
• 22 Wells A U, Cullinan P, Hansell D M et al.. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis.  Am J Respir Crit Care Med. 1994;  149 1583-1590
• 23 Marie I, Hachulla E, Cherin P et al.. Interstitial lung disease in polymyositis and dermatomyositis.  Arthritis Rheum. 2002;  47 614-622
• 24 Staples C A, Muller N L, Vedal S, Abboud R, Ostrow D N, Miller R R. Usual interstitial pneumonia: correlation of CT with clinical, functional and radiologic findings.  Radiology. 1987;  162 377-381
• 25 Wells A U, King A D, Rubens M B, Cramer D, du Bois R M, Hansell D M. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin section computed tomography.  Am J Respir Crit Care Med. 1997;  155 1367-1375
• 26 Wells A U, Desai S R, Rubens M B et al.. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed on computed tomography.  Am J Respir Crit Care Med. 2003;  167 962-969
• 27 Wells A U, Hansell D M, Rubens M B et al.. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography.  Arthritis Rheum. 1997;  40 1229-1236
• 28 Strickland N H, Hughes J M, Hart D A, Myers M J, Lavender J P. Cause of regional ventilation-perfusion mismatching in patients with idiopathic pulmonary fibrosis: a combined CT and scintigraphic study.  AJR Am J Roentgenol. 1993;  161 719-725
• 29 Tashkin D P, Elashoff R, Clements P J for the Scleroderma Lung Study Research Group et al. Cyclophosphamide versus placebo in scleroderma lung disease.  N Engl J Med. 2006;  354 2655-2666
• 30 Latsi P I, Wells A U. Evaluation and management of alveolitis and interstitial lung disease in scleroderma.  Curr Opin Rheumatol. 2003;  15 748-755
• 31 Steen V. Predictors of end stage lung disease in systemic sclerosis [editorial].  Ann Rheum Dis. 2003;  62 97-99
• 32 Cosgrove G P, Brown K K, Schiemann W P, Seris A E, Parr J E, Geraci M W. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis.  Am J Respir Crit Care Med. 2004;  170 242-251
• 33 Watters L C, King T E, Schwarz M I, Waldron J A, Stanford R E, Cherniack R M. A clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis.  Am Rev Respir Dis. 1986;  133 97-103
• 34 King T E, Tooze J A, Schwarz M I, Brown K R, Cherniack R M. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.  Am J Respir Crit Care Med. 2001;  164 1171-1181
• 35 Marciniuk D D, Gallagher C G. Clinical exercise testing in interstitial lung disease.  Clin Chest Med. 1994;  15 287-303
• 36 Lama V N, Flaherty K R, Toews G B et al.. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia.  Am J Respir Crit Care Med. 2003;  168 1084-1090
• 37 Eaton T, Young P, Milne D, Wells A U. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia.  Am J Respir Crit Care Med. 2005;  171 1150-1157
• 38 Hallstrand T S, Boitano L J, Johnson W C, Spada C A, Hayes J G, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis.  Eur Respir J. 2005;  25 96-103
• 39 Buch M H, Denton C P, Furst D E et al.. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test.  Ann Rheum Dis. 2007;  66 169-173
• 40 Hyland R H, Gordon D A, Broder I et al.. A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis.  J Rheumatol. 1983;  10 395-405
• 41 Hebert C A, Byrnes T J, Boethge B A et al.. Exercise limitation in patients with polymyositis.  Chest. 1990;  98 352-357
• 42 Nathan S D, Shlobin O A, Ahmad S, Urbanek S, Barnett S D. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis.  Chest. 2007;  131 657-663
• 43 Steen V D, Graham G, Conte C, Owens G, Medsger Jr T A. Isolated diffusing capacity reduction in systemic sclerosis.  Arthritis Rheum. 1992;  35 765-770
• 44 Latsi P I, du Bois R M, Nicholson A G et al.. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.  Am J Respir Crit Care Med. 2003;  168 531-537
• 45 Collard H R, King Jr T E, Bartelson B B, Vourlekis J S, Schwarz M I, Brown K K. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 2003;  168 538-542
• 46 Flaherty K R, Mumford J A, Murray S et al.. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.  Am J Respir Crit Care Med. 2003;  168 543-548
• 47 American Thoracic Society . Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement.  Am J Respir Crit Care Med. 2000;  161 646-664
• 48 Bouros D, Wells A U, Nicholson A G et al.. Histopathological subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.  Am J Respir Crit Care Med. 2002;  165 1581-1586